Skip to content

Titration of Buprenorphine and Naloxone Combination in Poppy Husk Users

TITRATION OF BUPRENORPHINE AND NALOXONE COMBINATION DOSE IN PATIENTS DEPENDENT ON POPPY HUSK: A PROSPECTIVE OPEN LABEL STUDY

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034326
Enrollment
20
Registered
2021-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: Buprenorphine and Naloxone combination: Patients attending OST clinic or psychiatry OPD who meet criteria for opioid dependence and are willing to participate will be admitted for inpat

Sponsors

ALL INDIA INSTITUTE OF MEDICAL SCIENCES RAIPUR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Diagnosed as a patient of opioid dependence as per ICD 10 Diagnostic and clinical Research criteria for dependence (F11) -Not On opioid substitution therapy for last 2 months -Only poppy husk User -Informed consent for participant

Exclusion criteria

Exclusion criteria: -Patient dependent on any other substance except Nicotine And Caffeine - Using opioid in any form other than natural (synthetic, semi synthetic, prescribed medication etc) for 6 months. - Patient of other organic brain disorder or of mental retardation and any other psychiatric disorder. - Patient of any unstable medical illness requiring priority management.

Design outcomes

Primary

MeasureTime frame
To come up with an appropriate and optimal dose of OST for initiation of treatment in patients dependent to natural opioids.Timepoint: Baseline: Titration of dose of OST in 1 week of in-patient admission. Follow up of patient on the titrated, on day 15 and day 30 after discharge from hospital

Secondary

MeasureTime frame
-to gauge patientsâ?? satisfaction with the current treatment modality. Timepoint: Baseline: During in patient admission Follow up: On day 15 and day 30 after discharge from hospital;to see the side effect profile of buprenorphine and naloxone combinationTimepoint: Baseline: During in patient admission Follow up: On day 15 and day 30 after discharge from hospital

Countries

India

Contacts

Public ContactMilan Arora

AIIMS, Raipur

singhlokesh123@gmail.com8103624062

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026